Eric Chanie Merck Group
Eric Chanie Merck Group
After an electronic engineering degree in France complemented by an MBA in Marketing, Eric Chanie joined a start-up company as Research & Development director involved in gas analysis for odor measurement. The company grew from 3 people to more than 100 with a successful IPO on the Paris stock exchange. In 2007, He then joined a medical device company developing miniaturized sensors for hemodialysis and neurosurgery (biosensing, intracranial pressure measurement) in which he leads the Research and Development team. He joined Merck Serono in 2010 as Medical Device innovation manager to strengthen product portfolio and contribute to the new generation of electronic devices. He was then appointed head of innovation in the newly created “Global Business Franchise Medical Devices” and got much more involved in business development and technology scouting in the space of digital health, AI & digital therapeutics. Eric joined a research organization in 2020 and co-founded a company called Epios, providing precision care for brain disorders enabled by implantable long-term brain sensing technology. In 2023, Eric joined back Merck as the head of device engineering and core team leader for connected pens.